For the next two weeks, I will be working with Gilead Sciences, a worldwide pharmaceutical firm known for its groundbreaking Hepatitis C and HIV drugs. They’re also starting to work more in the cancer sector, with over a dozen clinical trials in the pipeline. Although I don’t know all the details yet, I have heard that Evan and I will work on a project of some kind for a large portion of the WEP, as well as working in their Raleigh office.
Matthew